Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin plus CHEP in previously untreated CD30-positive peripheral T-cell lymphomas
2021-003526-80Phase 2Active
- Sponsor
- Kooperativní lymfomová skupina
- Start
- Sep 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in peripheral T-cell lymphoma (PTCL) and angioimmunoblastic T-cell lymphoma (AITL), sponsored by Kooperativní lymfomová skupina. Started Sep 2021; status: active.
02
Drugs
brentuximab vedotin
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on 2021-003526-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003526-80.